TNFAIP3 Gene Expression in Ankylosing Spondylitis and Psoriatic Arthritis Patients and Its Relation to Disease Activity

Status

Not yet recruiting

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07507487

Enrollment

110

Registered

2026-04-02

Start date

2026-04-01

Completion date

2029-07-01

Last updated

2026-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ankylosing Spondylitis and Psoriatic Arthritis Patients

Brief summary

1. Identify gene expression of TNFAIP3 in ankylosing spondylitis and psoriatic arthritis patients. 2. Detect relation between TNFAIP3 and disease activity. Inclusion criteria: 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984 (10). 2. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010) (11). b. Exclusion criteria: Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Interventions

DIAGNOSTIC_TESTDetection of TNFAIP3 gene expression by real time PCR.

Detection of TNFAIP3 gene expression by real time PCR.

Study design

Allocation

RANDOMIZED

Intervention model

SEQUENTIAL

Primary purpose

DIAGNOSTIC

Masking

DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

\- 1. Patients diagnosed with ankylosing spondylitis according to Modified New York classification criteria 1984. 2\. Patients diagnosed with psoriatic arthritis (PsA patients (age ≥18 years) who fulfilled the CASPAR classification criteria for PsA 2010)

Exclusion criteria

* Patients with erythrodermic or pustular psoriasis, pregnant and lactating females, patients with autoimmune diseases e.g. systemic lupus erythematosus, or major systemic diseases, and patients receiving any immunosuppressive drug will be excluded from the study.

Design outcomes

Primary

Measure	Time frame
Detection of TNFAIP3 gene expression. Ankylosing spondylitis (AS) is a chronic inflammatory condition primarily affecting the axial bone and sacroiliac joints. Its etiology involves genetic, environmental variables and demographic factors .	18 months

Secondary

Measure	Time frame
Detect relation between TNFAIP3 and ankylosing spondylitis apsoriatic arthritis activity. detection of TNFAIP3 gene expression by real time PCR will be done for every subject.	20 months

Contacts

CONTACTasmaa mohmed, master

a94asmaa@gmail.com01024850070

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026